Medical artificial intelligence (AI) solution development company VUNO gained the Class IIa CE markings for five of their AI solutions.

June 24, 2020 — Medical artificial intelligence (AI) solution development company VUNO gained the Class IIa CE markings for five of their AI solutions.

The five CE marked solutions are: VUNO Med-BoneAge, VUNO Med-DeepBrain, VUNO Med-Chest X-Ray, VUNO Med–Fundus AI and VUNO Med–LungCT AI. These products can now be commercialized and sold in 27 member states of the European Union, the Acceding countries as well as EFTA states. They can also make inroads into countries that recognize the European CE mark such as those in the Middle East, Asia, South and Central America, and Africa.

VUNO was assessed and deemed to meet EU safety and health protection requirements by a Notified Body based on a more stringent clinical validation standards and medical device guidelines. The efficacy and safety of those products demonstrated by a series of clinical research results and papers published in high impact journals and prestigious international seminars were of great help to satisfy the strict requirements.

Of the five MFDS (Ministry of Food and Drug Safety) approved products, four products (VUNO Med-Fundus AI, VUNO Med-Chest X-ray, and VUNO Med - BoneAge and VUNO Med Lung CT AI) received regulatory approval based on the proven effectiveness of performance through clinical trials. With such a robust portfolio, it is anticipated that VUNO Med solutions are to be used as key diagnostic supporting tools across many different medical environments overseas.

Hyun-Jun Kim, CEO of VUNO explained that, "We have been taking proper measures to ensure that VUNO's products obtain classification commensurate with their intended purposes as medical diagnostic supporting tools". He also added that, "In this sense, obtaining CE certification for all five products holds a great significance, and this will be able to accelerate our push for much anticipated global supply of VUNO Med series all around the world."

VUNO has been graining great traction at home and abroad with more than 100 active users of hospitals in Korea alone and is ready to deploy the CE marked products to international business partners and clients across different markets.

For more information: www.vuno.co


Related Content

News | Radiology Business

March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...

Time March 13, 2026
arrow
News | Enterprise Imaging

Mar. 9, 2026 — GE HealthCare recently announced that View, the viewer within the Genesis Radiology Workspace, has ...

Time March 12, 2026
arrow
News | Stroke

March 11, 2026 — Brainomix, a provider of AI-powered imaging tools for stroke and lung fibrosis, has announced the ...

Time March 11, 2026
arrow
News | HIMSS

March 9, 2026 — Fujifilm Healthcare Americas Corp. is showcasing how its latest AI-powered enterprise imaging solutions ...

Time March 10, 2026
arrow
News | FDA

Mar. 9, 2026 — GE HealthCare's View, the powerful viewer within the Genesis Radiology Workspace, has received 510(k) ...

Time March 09, 2026
arrow
News | HIMSS

March 5, 2026 — At the Health Information and Management Systems Society (HIMSS) Conference & Exhibition 2026 in Las ...

Time March 06, 2026
arrow
News | Radiology Business

March 5, 2026 — Cassling is now accepting applications for the 2026 Imaging for Impact Award, a national recognition ...

Time March 05, 2026
arrow
News | Radiation Oncology

March 4, 2026 — Lunit has announced that 21 studies featuring its AI solutions will be presented at the European ...

Time March 05, 2026
arrow
News | Ultrasound Women's Health

March 2, 2026 — Ultrasound AI, a provider of artificial intelligence applications for medical imaging, has received FDA ...

Time March 03, 2026
arrow
News | FDA

Feb. 26, 2026 — The U.S. Food and Drug Administration (FDA) has given 510(k) class II clearance of qXR-Detect, the ...

Time February 26, 2026
arrow
Subscribe Now